British Patient Capital (BPC) has launched its Life Sciences Investment Programme, which will make investments in UK-focused, later-stage life sciences funds.
Calucem reports a turnover of EUR 58m, with an EBITDA of EUR 16m
Should Apex make a firm offer, Cinven would have to significantly up its own bid for the fund administrator
Third exit announced by Lonsdale this year, and the second from its 2016 fund
Paris-based private equity firm is exploring options around a dual-track process